Premaitha Health has entered into an extension of the investment agreement with Thermo Fisher Scientific announced on 14 December 2015, further developing this important relationship.
Premaitha is a developer of the leading CE-marked complete non-invasive prenatal screening system.
Under the terms of the agreement, Thermo Fisher will make available to Premaitha an additional secured loan facility of £4.0m (the "Loan"), which will be drawn down against future milestones.
The new loan facility follows on from the existing facility, announced on 14 December 2015, on similar terms. Specifically, interest on amounts drawn on the Loan will accrue at a rate of 6 per cent per annum payable quarterly in arrears or will be capable of conversion to loan principal.
The Loan is repayable on 14 December 2023, with the option to repay sooner. Under the terms of the Loan, Premaitha will issue Thermo Fisher warrants over 17,094,018 new ordinary shares in the Company exercisable at 11.7 pence ("2016 Warrants"), being a premium of 10% over the closing share price on 21 September 2016 (the last business day prior to issue of the 2016 Warrants).
A second tranche of warrants will be issued on 1 April 2017, or earlier if loan drawdowns exceed £2.0m, over new ordinary shares in the Company at a premium of 10% over the closing share price on the last business day prior to the date of issue.
At 9:57am: (LON:NIPT) Premaitha Health Plc share price was 0p at 10.63p